[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1974

Prophylaxis and Therapy of Experimental Ocular Herpes SimplexComparison of Idoxuridine, Adenine Arabinoside, and Hypoxanthine Arabinoside

Author Affiliations

From the Department of Cornea Research, Virology-Uveitis Laboratory, Retina Foundation, Boston.

Arch Ophthalmol. 1974;92(5):417-421. doi:10.1001/archopht.1974.01010010429012
Abstract

Studies comparing the antiviral drugs idoxuridine, adenine arabinoside, and 15%, 10%, and 3% hypoxanthine arabinoside reveal that the first three drugs all have equal therapeutic efficacy in treatment of established herpes simplex keratoconjunctivitis. The idoxuridine and all hypoxanthine arabinoside formulations are equally effective in antiviral prophylaxis. Hypoxanthine arabinoside is the highly soluble natural metabolite of adenine arabinoside and has the advantages over idoxuridine of intraocular penetration and lack of tissue toxicity.

References
1.
Pavan-Langston D, Dohlman CH:  A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis . Am J Ophthalmol 74:81-88, 1972.
2.
Bellows JG:  Limitations of IDU in herpetic keratitis; cryotherapy as an alternative . Can J Ophthalmol 4:123-127, 1969
3.
Sidwell RW, et al:  The antiviral activity 9-B-D arabinofuranosyladenine (Ara A): II. Activity against herpes simplex keratitis in hamsters . Antimicrob Agents Chemother 13:148-154, 1968.
4.
Langston RHS, Pavan-Langston D, Dohlman CH: Antiviral medication and corneal wound healing. Arch Ophthalmol, to be published.
5.
Pavan-Langston D, Dohlman CH, Geary PA, et al:  Intraocular penetration of Ara A and IDU, therapeutic implications in clinical herpetic uveitis . Trans Am Acad Ophthalmol Otolaryngol 77:455-466, 1973.
6.
Prusoff WH, Jaffee JJ, Gunther H:  Studies in the mouse of the pharmacology of 5 iododeoxyuridine, and analogue of thymidine . Biochem Pharmacol 3:110-121, 1960.Article
7.
Nemes MM, Hilleman MR:  Effective treatment of experimental herpes simplex keratitis with a new derivative, 5 methylamino-2-deoxyaridine (MADU) . Proc Soc Exp Biol Med 119:515-520, 1965.Article
8.
Wellings PC, et al:  Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers . Am J Ophthalmol 73:932-942, 1972.
9.
Hyndiuk RA, Kaufman H:  Newer compounds in therapy of herpes simplex keratitis . Arch Ophthalmol 78:600-605, 1967.Article
10.
Pharmaceutical Development Department report . Detroit, Parke, Davis & Co., Feb 14, 1972, pp 1-6.
×